Results 81 to 90 of about 3,569 (208)

Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol

open access: yes, 2013
Currently beta-adrenergic receptor blockers are considered to be potential drugs under investigation for preventive or therapeutic effect in osteoporosis.
Bhat, MR   +3 more
core   +1 more source

Die Wirkung von Etelcalcetid versus Alfacalcidol auf soluble Klotho in Hämodialysepatienten mit linksventrikulärer Hypertrophy

open access: yes, 2020
In früheren Studien wurde festgestellt, dass soluble Klotho (sKl) ein Prädiktor für Nierenschädigungen und chronische Nierenerkrankungen (CKD) ist.
Steinringer, Stefan
core  

Modern views on the etiology, pathogenesis, diagnosis, prevention and treatment of vitamin D deficiency in postmenopausal women (literature review) [PDF]

open access: yesГинекология, 2016
In the literary review is presented the modern data showing different forms of vitamin D deficiency and its optimal ways of correction. It specifies the pathway of vitamin D in the body.
T Yu Pestrikova, T V Yachinskaya
doaj  

Experimental design.

open access: yes, 2018
5/6 Nx = 5/6 nephrectomy, Ctrl = control, CRF = chronic renal failure, HP = high phosphate, NP = normal phosphate, D = alfacalcidol, ICG = ICG-001, Veh = Vehicle, 8w = 8weeks. After four weeks of uremia CRF rats were allocated to five experimental groups
Carsten Nielsen (5593808)   +8 more
core   +1 more source

The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study [PDF]

open access: yes, 2014
BACKGROUND: The risk of cardiovascular disease is tremendously high in dialysis patients. Dialysis patients treated with vitamin D analogs show decreased cardiovascular morbidity and mortality compared with untreated patients.
Bruunsgaard, H.   +14 more
core   +2 more sources

Prophylactic Use of Alfacalcidol in Corticosteroid-Induced Osteoporosis

open access: yes, 1999
peer reviewedOne hundred and forty-five patients suffering from diseases requiring long-term treatment with high doses of corticosteroids (30 mg/day or greater of prednisolone) were recruited to the study. Patients had to be steroid naive on entry to the
Menkes, C. J.   +6 more
core   +1 more source

Alendroninezuur effectiever dan alfacalcidol voor preventie van osteoporose bij patiënten met een reumatische ziekte die starten met glucocorticoïdtherapie [PDF]

open access: yes, 2007
OBJECTIVE: To compare the effects of alendronate and alfacalcidol in the prevention ofglucocorticoid-related osteoporosis in patients with a rheumatic disease. DESIGN: Randomised, double-blind, double-placebo clinical trial (www.
Buskens, E.; id_orcid   +12 more
core   +3 more sources

Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease

open access: yesТерапевтический архив, 2014
AIM: To evaluate the efficacy and safety of alfacalcidol and paracalcitol used to correct impaired phosphorus-calcium metabolism (PCM) in patients with predialysis chronic kidney disease (CKD)/MATERIAL AND METHODS: Examinations were made in 128 patients ...
L Iu Milovanova   +2 more
doaj  

Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women [PDF]

open access: yes, 2007
We studied the differences of therapeutic effects on regional bone mineral density (BMD) and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
Yasui, Natsuo   +12 more
core  

Diagram of the experimental protocol.

open access: yes, 2018
OLETF rats were assigned to each treatment group. Each treatment began at the age of 20 weeks. OLETF = Otsuka Long-Evans Tokushima Fatty; LETO = Long-Evans Tokushima Otsuka (non-diabetic control); Cont = control (diabetic control); ALF = alfacalcidol ...
Yusuke Yuasa (5866529)   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy